Lonza Group Past Earnings Performance
Past criteria checks 1/6
Lonza Group has been growing earnings at an average annual rate of 10.4%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 6.8% per year. Lonza Group's return on equity is 6.9%, and it has net margins of 9.7%.
Key information
10.4%
Earnings growth rate
10.5%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 6.8% |
| Return on equity | 6.9% |
| Net Margin | 9.7% |
| Next Earnings Update | 14 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Lonza Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 6,717 | 654 | 940 | 105 |
| 30 Sep 23 | 6,518 | 892 | 946 | 100 |
| 30 Jun 23 | 6,319 | 1,129 | 951 | 95 |
| 31 Mar 23 | 6,271 | 1,172 | 958 | 95 |
| 31 Dec 22 | 6,223 | 1,215 | 965 | 95 |
| 30 Sep 22 | 6,036 | 1,062 | 965 | 93 |
| 30 Jun 22 | 5,849 | 909 | 964 | 90 |
| 31 Mar 22 | 5,629 | 792 | 930 | 90 |
| 31 Dec 21 | 5,409 | 674 | 896 | 90 |
| 30 Sep 21 | 5,108 | 612 | 868 | 87 |
| 30 Jun 21 | 4,807 | 550 | 839 | 84 |
| 31 Mar 21 | 4,658 | 640 | 840 | 84 |
| 31 Dec 20 | 4,508 | 730 | 840 | 84 |
| 30 Sep 20 | 3,135 | 656 | 476 | 117 |
| 30 Jun 20 | 3,474 | 696 | 604 | 75 |
| 31 Mar 20 | 3,841 | 672 | 704 | 75 |
| 31 Dec 19 | 4,207 | 647 | 804 | 75 |
| 30 Sep 19 | 5,821 | 710 | 1,183 | 55 |
| 30 Jun 19 | 5,722 | 658 | 1,068 | 110 |
| 31 Mar 19 | 5,632 | 657 | 1,050 | 110 |
| 31 Dec 18 | 5,542 | 655 | 1,032 | 110 |
| 30 Jun 18 | 5,034 | 826 | 929 | 95 |
| 31 Mar 18 | 4,791 | 745 | 880 | 95 |
| 31 Dec 17 | 4,548 | 664 | 831 | 95 |
| 30 Sep 17 | 4,758 | 527 | 891 | 94 |
| 30 Jun 17 | 4,423 | 334 | 833 | 84 |
| 31 Mar 17 | 4,278 | 318 | 783 | 84 |
| 31 Dec 16 | 4,132 | 301 | 732 | 84 |
| 30 Sep 16 | 4,025 | 331 | 672 | 94 |
| 30 Jun 16 | 3,918 | 360 | 611 | 103 |
| 31 Mar 16 | 3,861 | 319 | 574 | 103 |
| 31 Dec 15 | 3,803 | 277 | 536 | 103 |
| 30 Sep 15 | 3,774 | 243 | 529 | 102 |
| 30 Jun 15 | 3,744 | 208 | 521 | 101 |
| 31 Mar 15 | 3,692 | 223 | 520 | 101 |
| 31 Dec 14 | 3,640 | 237 | 519 | 101 |
| 30 Sep 14 | 3,640 | 212 | 490 | 106 |
| 30 Jun 14 | 3,640 | 186 | 460 | 110 |
| 31 Mar 14 | 3,612 | 137 | 445 | 110 |
| 31 Dec 13 | 3,584 | 87 | 429 | 110 |
| 30 Sep 13 | 3,645 | 109 | 623 | 113 |
| 30 Jun 13 | 3,705 | 131 | 816 | 116 |
Quality Earnings: LZAG.F has a large one-off loss of CHF498.0M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: LZAG.F's current net profit margins (9.7%) are lower than last year (19.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LZAG.F's earnings have grown by 10.4% per year over the past 5 years.
Accelerating Growth: LZAG.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: LZAG.F had negative earnings growth (-46.2%) over the past year, making it difficult to compare to the Life Sciences industry average (-6.6%).
Return on Equity
High ROE: LZAG.F's Return on Equity (6.9%) is considered low.